Spyre Therapeutics, Inc. SYRE Proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs
Proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept syre:ProceedsFromIssuanceOfCommonStockFollowOnOfferingsNet.
The official record: Spyre Therapeutics, Inc.’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs?
- Spyre Therapeutics, Inc. (SYRE) reported proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs of $74.1M in Q4 2025.
- How has Spyre Therapeutics, Inc.'s proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs changed year-over-year?
- Spyre Therapeutics, Inc.'s proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs increased by 37.3% year-over-year, from $53.97M to $74.1M.
- What does proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs mean?
- This represents cash raised through a structured follow-on public offering of common stock. Unlike ATM programs, these are typically larger, singular events used to fund significant R&D milestones or corporate expansion.